On July 8, 2025, JMP Securities analyst Silvan Tuerkcan announced a significant adjustment to the price target for Jasper Therapeutics (JSPR, Financial). The investment firm has maintained its "Market Outperform" rating for the biotech company, signaling continued confidence in its market potential.
However, the price target for JSPR has been substantially lowered from $70.00 to $12.00. This adjustment represents a notable decrease of 82.86%. The change reflects the current assessment of market conditions and company performance as evaluated by JMP Securities.
JSPR continues to attract attention in the market, and investors will be watching closely to see how Jasper Therapeutics navigates the evolving landscape in the biotech sector. As always, stakeholders are advised to keep abreast of further developments and performance metrics related to JSPR.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Jasper Therapeutics Inc (JSPR, Financial) is $29.13 with a high estimate of $70.00 and a low estimate of $4.00. The average target implies an upside of 810.47% from the current price of $3.20. More detailed estimate data can be found on the Jasper Therapeutics Inc (JSPR) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Jasper Therapeutics Inc's (JSPR, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
